Francois Brisebois, an analyst from LifeSci Capital, maintained the Buy rating on Savara. The associated price target remains the same with $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Francois Brisebois has given his Buy rating due to a combination of factors that highlight the potential of Savara’s product, MOLBREEVI, in treating Autoimmune Pulmonary Alveolar Proteinosis (APAP). The upcoming discussion with Dr. Ali Ataya, an expert in pulmonary diseases, underscores the significance of MOLBREEVI’s clinical data and its safety and efficacy profile, which are crucial for its commercial success.
Furthermore, the report suggests that the commercial potential of MOLBREEVI in the APAP market is promising, given the current treatment landscape. The engagement of key opinion leaders like Dr. Ataya in discussions about MOLBREEVI indicates a strategic approach to understanding and capitalizing on market opportunities, which supports the Buy recommendation.
In another report released on November 14, Oppenheimer also maintained a Buy rating on the stock with a $9.00 price target.